Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Harrow, Inc. (HROW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34.38, with a market capitalisation of $1.28B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $28.54 to $54.85. This page covers its latest market performance, valuation, price trends and company information.
$1.28B | |
$33.85 | |
$59.23 | |
$3.33 | |
$33.84 | |
87.55K | |
609.77K | |
-- | |
$54.85 | |
$28.54 | |
-- | |
-- |
Harrow, Inc. (HROW) is currently trading at $34.38 as of 2026-09-16 14:39:00, up 1.60% ($0.54) from the previous close of $33.84
During today's regular trading session, HROW has traded between $3.33 and $59.23, with a trading volume of 87.55K shares. The current price is near the middle of today's range.
Over the past seven days, Harrow, Inc. (HROW) moved from $38.54 to $34.38, representing a decline of 10.79% ($4.16).
The stock traded between $33.00 and $38.67 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 505.93 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.2%
HROW is currently trading at $34.38, placing it 22.2% of the way from its 52-week low of $28.54 to its 52-week high of $54.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 373 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harrow, Inc. (HROW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.